Insulet PODD Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| Drug Delivery | $22.5M-50.1% | $34.1M-12.3% | $44M+22.6% | $47.2M+30.0% | $45.1M+2.0% | |
| International | $844.9M+50.8% | $754.3M+44.1% | $682.2M+39.9% | $618M+36.9% | $560.4M+31.3% | |
| Total Omnipod products | $2.88B+33.7% | $2.67B+31.6% | $2.48B+27.2% | $2.31B+25.9% | $2.15B+24.0% | |
| U.S.Omnipod | $2.03B+27.6% | $1.92B+27.2% | $1.8B+23.0% | $1.69B+22.3% | $1.59B+21.7% | |
| Property, plant and equipment, net by Geography | ||||||
| Malaysia | $769.8M— | $702.9M— | $642M— | —— | —— | |
| Other | $304.9M— | $182M— | $64.8M— | —— | —— | |
| U.S. | $1.87B— | $1.87B— | $1.88B— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Insulet break its business down?
- Insulet (PODD) reports total revenue by product across 4 parts — Drug Delivery, International, Total Omnipod products and U.S.Omnipod. Each is extracted from the segment footnotes and tracked over time.
- Where does Insulet's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insulet's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
